Last reviewed · How we verify
propofol injectable emulsion
Propofol is a sedative-hypnotic agent that enhances inhibitory GABA neurotransmission in the central nervous system to produce rapid unconsciousness and sedation.
Propofol is a sedative-hypnotic agent that enhances inhibitory GABA neurotransmission in the central nervous system to produce rapid unconsciousness and sedation. Used for Induction of general anesthesia, Maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.
At a glance
| Generic name | propofol injectable emulsion |
|---|---|
| Sponsor | Life Extension Foundation Inc. |
| Drug class | Sedative-hypnotic |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization. This results in rapid onset of sedation and anesthesia. It is commonly used for induction and maintenance of general anesthesia, as well as for sedation in intensive care settings.
Approved indications
- Induction of general anesthesia
- Maintenance of general anesthesia
- Sedation in mechanically ventilated patients in intensive care units
Common side effects
- Hypotension
- Respiratory depression
- Pain on injection
- Bradycardia
- Apnea
- Propofol infusion syndrome (with prolonged use)
Key clinical trials
- Propofol vs Remifentanil for Sedation in Gastroscopy (NA)
- A Study of Remimazolam Tosilate for Sedation in the ICU (PHASE3)
- Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia (PHASE3)
- Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery (PHASE3)
- Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery (PHASE3)
- Bioequivalence Study of Propofol Medium and Long Chain Fat Emulsion Injection in Healthy Chinese Subjects (PHASE1)
- Respiratory Effect of the LISA Method with Sedation by Propofol Versus Absence of Sedation. (PHASE3)
- Postoperative Quality of Recovery After General Anesthesia With Remimazolam (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- propofol injectable emulsion CI brief — competitive landscape report
- propofol injectable emulsion updates RSS · CI watch RSS
- Life Extension Foundation Inc. portfolio CI